A Phase I Study of DT2219ARL (IND100780), a Bispecific Chain Immunotoxin for the Treatment of CD19(+), CD22 (+) B-Lineage Leukemia or Lymphoma

Trial Profile

A Phase I Study of DT2219ARL (IND100780), a Bispecific Chain Immunotoxin for the Treatment of CD19(+), CD22 (+) B-Lineage Leukemia or Lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs DT2219ARL (Primary)
  • Indications B cell lymphoma; Leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Aug 2017 According to GT Biopharma media release, company changed its name from OXIS International to GT Biopharma.
    • 09 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 22 Jan 2016 Planned End Date changed from 1 Nov 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top